{"id":"ly353381","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Leg cramps"},{"rate":null,"effect":"Vaginal bleeding or spotting"},{"rate":null,"effect":"Thromboembolic events"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a SERM, LY353381 binds to estrogen receptors with tissue-selective activity, functioning as an agonist in bone and cardiovascular tissues while acting as an antagonist in breast and endometrial tissues. This selective profile aims to provide the bone-protective and lipid-modifying benefits of estrogen replacement while avoiding the increased risks of breast cancer and endometrial proliferation associated with traditional hormone replacement therapy.","oneSentence":"LY353381 is a selective estrogen receptor modulator (SERM) that acts as a partial agonist at estrogen receptors to provide bone-protective and cardiovascular benefits without stimulating breast or endometrial tissue.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:54.160Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoporosis prevention and treatment in postmenopausal women"},{"name":"Cardiovascular risk reduction in postmenopausal women"}]},"trialDetails":[{"nctId":"NCT00005879","phase":"PHASE2","title":"LY353381 in Preventing Breast Cancer in Women With Hyperplasia","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2000-08","conditions":"Breast Cancer","enrollment":199},{"nctId":"NCT00005886","phase":"PHASE1","title":"Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2000-07","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00767299","phase":"PHASE2","title":"A Study of Arzoxifene to Treat Korean Women With Osteoporosis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-12","conditions":"Osteoporosis","enrollment":91},{"nctId":"NCT00003428","phase":"PHASE2","title":"Hormone Therapy in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1998-05","conditions":"Breast Cancer","enrollment":114},{"nctId":"NCT00003669","phase":"PHASE2","title":"Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"1998-11","conditions":"Endometrial Cancer","enrollment":""},{"nctId":"NCT00003670","phase":"PHASE2","title":"Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"1998-10","conditions":"Ovarian Cancer, Primary Peritoneal Cavity Cancer","enrollment":""},{"nctId":"NCT00253539","phase":"PHASE2","title":"Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2002-01","conditions":"Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2)","enrollment":3},{"nctId":"NCT00088010","phase":"PHASE3","title":"Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2004-06","conditions":"Osteoporosis, Postmenopausal","enrollment":9369},{"nctId":"NCT00383422","phase":"PHASE3","title":"Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-10","conditions":"Osteoporosis, Postmenopausal","enrollment":320},{"nctId":"NCT00190697","phase":"PHASE4","title":"A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2001-01","conditions":"Breast Cancer, Endometrial Cancer, Ovarian Cancer","enrollment":70},{"nctId":"NCT00085956","phase":"PHASE3","title":"Effects of Arzoxifene on Bone Mass and the Uterus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2004-04","conditions":"Postmenopausal Bone Loss","enrollment":300},{"nctId":"NCT00034125","phase":"PHASE3","title":"Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"","conditions":"Breast Neoplasms","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"LY353381","genericName":"LY353381","companyName":"Eli Lilly and Company","companyId":"eli-lilly-and-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LY353381 is a selective estrogen receptor modulator (SERM) that acts as a partial agonist at estrogen receptors to provide bone-protective and cardiovascular benefits without stimulating breast or endometrial tissue. Used for Osteoporosis prevention and treatment in postmenopausal women, Cardiovascular risk reduction in postmenopausal women.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}